AstraZeneca is looking for partnerships in diseases that are outside but complementary to core therapy areas
AstraZeneca is a global, innovation-driven, integrated biopharmaceutical company. They discover, develop, manufacture and market prescription medicines for six important areas of healthcare, which include some of the world’s most serious illnesses: cancer, cardiovascular, gastrointestinal, infection, neuroscience, and respiratory and inflammation.
Their research has breadth, and depth and focuses on disease areas where AstraZeneca and their partners can make the most meaningful impact on patients’ lives. Innovative Medicine’s Units (iMeds) are responsible for driving research from discovery to early development in their core therapeutic areas, while New Opportunities group looks for strategic areas of focus outside their core disease areas.
The New Opportunities group seeks to identify new therapeutics in diseases that are outside but complementary to AstraZeneca’s core therapy areas.
They are focused on identifying small and large molecule clinical-stage projects from external sources in addition to forming collaborations around novel indications for a range of internal drug projects.
Disease areas of particular interest include, but are not exclusive to,
- hearing disorders
- critical care
- women’s health
- supportive care
- wound healing
- acute kidney injury
- dermatology and